Introgen Therapeutics Inc

Premium Company Profile

Publication Date	April 2008
Publisher	Datamonitor
Product Type	Report
Pages	53
ISBN Number	not applicable
Product Code	DAT11502

Price

£265.00
approximately: $521 | €337

PDF

PRINT £315 ($619 | €400)

Order above formats by FAX

Summary

Introduction

Introgen Therapeutics (Introgen) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer. The company has been successful in developing a strong portfolio of pipeline candidates using its 'Enabling Technologies'.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company's product candidates include includes five clinical-stage product candidates: ADVEXIN and INGN 241 in Phase III clinical trials for head and neck cancer; INGN 225, a therapeutic p53 vaccine, in Phase II clinical development for lung and breast cancer. The company's INGN 234, a topical formulation for oral cancer prevention and treatment of oral pre-malignancies, in Phase I clinical development; and INGN 401, a systemic nanoparticle tumor suppressor is in Phase II clinical trials for metastatic lung cancer. The company recognizes revenues in the form of contract research fees from other pharmaceutical/biotechnology companies, and grants from academic and government organizations. The company's total revenues have slightly declined at a CAGR of 0.5% during 2002-2006, almost flat at $1.2 million.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .

Content

Overview
Catalyst
Summary
- Table of Figures
- Table of Tables
- Company Structure
- Company Overview and Key Facts
- Business Description
- Landmark Products and Services
- Enabling Technologies
- History
- M&a History
- Magnum Therapeutics
- Locations and Subsidiaries
- Company Financials
- Stock Market Performance
- P&l
- Balance Sheet
- Cash Flow
- Products & Services
- Pipeline Products
- in-House Pipeline
- Advexin
- Ingn 241
- Ingn 225
- Ingn 401
- Ingn 234
- Ingn 402
- Ingn 403
- Ingn 007
- Ac Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Broad Proprietary Pipeline
- Strong Intellectual Property
- Weaknesses
- Contract Manufacturing Services
- Opportunities
- Advexin Therapy
- Anti-Cancer Drug Market
- Threats
- Regulatory Impact on Nature of Business
- Conflicting Obligations
- Value Chain Analysis
- Overview
- Discovery and Product Development
- Manufacturing
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- David G Nance
- William H Cunningham
- S Malcolm Gillis
- Peter Barton Hutt
- John N Kapoor
- Charles E Long
- James W Albrecht
- C Channing Burke
- Max W Talbott
- Robert E Sobol
- J David Enloe
- Kerstin B Menander
- David L Parker
- Sunil Chada
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask The Analyst
- Datamonitor Consulting
- Disclaimer
List of Tables
- Table 1: Introgen - Key Facts
- Table 2: Introgen - Other Locations and Subsidiaries
- Table 3: Introgen - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 4: Introgen - Key Events Impacting Share Price Performance
- Table 5: Introgen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: Introgen - Operating Cost Ratio Analysis, 2002-2006 (% of Total Revenues)
- Table 7: Introgen - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: Introgen - Cash Flow, 2002-2006 ($ Mn)
- Table 9: Introgen - in-House Pipeline Products
- Table 10: Introgen - Forecast Sales, 2006-2010 ($ Mn)
- Table 11: Introgen - Key Competitors
- Table 12: Introgen - Key Suppliers
- Table 13: Introgen - Key Clients
- Table 14: Introgen - Key Shareholders
- Table 15: Introgen - SWOT Analysis Summary
- Table 16: Introgen - Value Chain Analysis
- Table 17: Introgen - Scorecard
- Table 18: Introgen - Key Employees
- Table 19: Introgen - Financial and Operational Overview
List of Figures
- Figure 1: Introgen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Introgen - Key Strategic Revenues, 2006-2010 ($ Mn)